David Hong
Experienced in Primitive Neuroectodermal Tumor (PNET)

Dr. David Hong

Neurosurgery
1250 S Cedar Crest Blvd Ste 400, 
Allentown, PA 
Experienced in Primitive Neuroectodermal Tumor (PNET)
1250 S Cedar Crest Blvd Ste 400, 
Allentown, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Hong is a Neurosurgery provider in Allentown, Pennsylvania. Dr. Hong is rated as an Experienced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Sunken Fontanelles, Bulging Fontanelles, Neuroendocrine Tumor, Posterior Fossa Decompression, and Gastric Bypass.

His clinical research consists of co-authoring 582 peer reviewed articles and participating in 29 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurosurgery
Licenses
Neurological Surgery in MI
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Independent Health
  • EPO
  • POS
  • PPO

Locations

1250 S Cedar Crest Blvd Ste 400, Allentown, PA 18103

Additional Areas of Focus

Dr. Hong has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
Phase I Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab, and Irinotecan in Patients With Advanced Colorectal Cancer
Phase I Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab, and Irinotecan in Patients With Advanced Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 03, 2025
Intervention Type: Biological, Drug, Other
Study Phase: Phase 1
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2025
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 1
A Phase 1 Study of LY3200882 in Patients With Solid Tumors
A Phase 1 Study of LY3200882 in Patients With Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1
Phase II Clinical Trial Evaluating Intravenous AZD9150 (Antisense STAT3) With MEDI4736 (Anti-PD-L1) in Patients With Advanced Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
Phase II Clinical Trial Evaluating Intravenous AZD9150 (Antisense STAT3) With MEDI4736 (Anti-PD-L1) in Patients With Advanced Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2025
Intervention Type: Biological, Drug
Study Drugs: Danvatirsen, Durvalumab
Study Phase: Phase 2
Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas
Enrollment Status: Completed
Publish Date: April 02, 2025
Intervention Type: Drug
Study Drug: SL-279252
Study Phase: Phase 1
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Genetic
Study Phase: Phase 1
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors
A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: December 12, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
Enrollment Status: Completed
Publish Date: September 27, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers
A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers
Enrollment Status: Terminated
Publish Date: September 04, 2024
Intervention Type: Genetic
Study Phase: Phase 2
A Phase 1b/2 Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)
A Phase 1b/2 Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)
Enrollment Status: Terminated
Publish Date: April 02, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced Malignancies
A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: March 21, 2024
Intervention Type: Biological, Drug
Study Drugs: Imatinib Mesylate, Ipilimumab
Study Phase: Phase 1
A Phase 1, Multicenter, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of hSTC810 Monotherapy in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of hSTC810 Monotherapy in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: March 13, 2024
Intervention Type: Biological
Study Drug: hSTC810
Study Phase: Phase 1
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2024
Intervention Type: Genetic, Radiation
Study Drug: Autologous Genetically Modified MAGE-A4c1032 T-Cells
Study Phase: Phase 1
Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Enrollment Status: Completed
Publish Date: September 02, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies
A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: February 10, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Enrollment Status: Completed
Publish Date: December 29, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Enrollment Status: Completed
Publish Date: September 09, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Enrollment Status: Completed
Publish Date: April 08, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Genetic
Study Phase: Phase 1
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors
A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors
Enrollment Status: Completed
Publish Date: April 01, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: July 19, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 24 Less Clinical Trials

582 Total Publications

Image-Guided Thermal Ablation in Patients With Locally Recurrent Non-Small Cell Lung Cancer After Stereotactic-Beam Radiation Therapy.
Image-Guided Thermal Ablation in Patients With Locally Recurrent Non-Small Cell Lung Cancer After Stereotactic-Beam Radiation Therapy.
Journal: AJR. American journal of roentgenology
Published: November 05, 2025
Similar Doctors
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Hugh D. Moulding
Neurosurgery
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Hugh D. Moulding
Neurosurgery

St Lukes Physician Group Inc

421 W Chew St, 
Allentown, PA 
 (2.7 miles away)
610-776-4959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hugh Moulding is a Neurosurgery provider in Allentown, Pennsylvania. Dr. Moulding is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Metastatic Brain Tumor, Awake Craniotomy, and Balloon Sinuplasty.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Kevin D. Judy
Neurosurgery
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Kevin D. Judy
Neurosurgery

Jefferson University Physicians

834 Chestnut St, Terrace Suite T 150, 
Philadelphia, PA 
 (46.4 miles away)
215-955-7246
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kevin Judy is a Neurosurgery provider in Philadelphia, Pennsylvania. Dr. Judy is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioma, Meningioma, Astrocytoma, Awake Craniotomy, and Gamma Knife Radiosurgery.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. David W. Andrews
Neurosurgery
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. David W. Andrews
Neurosurgery

Jefferson University Physicians

925 Chestnut St, Suite 3, 
Philadelphia, PA 
 (46.3 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Andrews is a Neurosurgery provider in Philadelphia, Pennsylvania. Dr. Andrews is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Meningioma, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), Awake Craniotomy, and Gamma Knife Radiosurgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hong's expertise for a condition
ConditionClose
      View All 82 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile